Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220720 · ClinicalTrials.gov registry record · Phase 2
POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions
A Phase 2 study of Prostate, sponsored by University of Florida.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07220720: Active Phase 2 study of Prostate, sponsored by University of Florida.
NCT07220720 is a Phase 2 study of Prostate that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 30 participants, below the 350-participant average among 5 other Prostate trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220720, a Phase 2 study of Prostate, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results. These uncertain results include MRI results that showed a PIRADS 2 or PIRADS 3 area on the prostate. The investigators want to find out if this new test is better to detect prostate cancer than just doing a biopsy based on MRI alone.
Primary Outcome
Evaluate the change in PPV for detecting clinically significant prostate cancer (csPCa) cores by comparing results from mpMRI alone (PIRADS 2 and 3 lesions) to the combination of mpMRI with flotufolastat F 18 PET-CT.
Conditions Studied
Interventions
- DRUG Flotufolastat F 18
Study Locations (1)
Florida
- UF Health - Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-04 |
| Est. Completion | 2032-11-15 |
| Phase | Phase 2 |
What the registry record for NCT07220720 still lists
NCT07220720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 350-participant average among 5 other Prostate trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Prostate appearing as the primary indexed condition, and to 1 intervention - of which Flotufolastat F 18 is the first listed.
NCT07220720 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07220720 about?
NCT07220720 is a clinical study titled "POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions". The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results. These uncertain results include MRI results that showed a PIRADS 2 or PIRADS 3 area on the prostate. The investigators wan...
What is the current status of trial NCT07220720?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-11-04. Estimated completion is 2032-11-15.
What conditions does trial NCT07220720 study?
This clinical trial studies the following conditions: Prostate.
What interventions are being tested in trial NCT07220720?
The interventions under investigation include: Flotufolastat F 18 (DRUG).
Who is sponsoring clinical trial NCT07220720?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220720 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
COMPLETED · Phase 2
-
Collection of Blood From Patients With Prostate Cancer
RECRUITING
-
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI